CLS Americas announces the full twenty patients have been safely treated in the Phase I clinical study titled, “Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.” The study utilizes CLS’s TRANBERG® Thermal Therapy System in combination with the Focalyx® Fusion medical device for treatment organization, planning, image fusion, and real-time image guidance during the high-precision, focal laser ablation (FLA) treatment.

The study is being conducted by Urological Research Network, LLC, a Florida-based, not-for-profit clinical research organization.

Read the full press release here.